On Tuesday, TG Therapeutics Inc (NASDAQ: TGTX) opened higher 1.40% from the last session, before settling in for the closing price of $34.98. Price fluctuations for TGTX have ranged from $15.16 to $46.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 2514.62%. Company’s average yearly earnings per share was noted 493.33% at the time writing. With a float of $142.95 million, this company’s outstanding shares have now reached $158.17 million.
Considering the fact that the conglomerate employs 338 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 87.41%, operating margin of 15.48%, and the pretax margin is 10.8%.
TG Therapeutics Inc (TGTX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of TG Therapeutics Inc is 9.96%, while institutional ownership is 62.74%. The most recent insider transaction that took place on Jan 03 ’25, was worth 343,443. In this transaction CFO of this company sold 11,337 shares at a rate of $30.29, taking the stock ownership to the 670,632 shares. Before that another transaction happened on Jan 06 ’25, when Company’s CFO sold 10,021 for $28.53, making the entire transaction worth $285,939. This insider now owns 660,611 shares in total.
TG Therapeutics Inc (TGTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 493.33% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Check out the current performance indicators for TG Therapeutics Inc (TGTX). In the past quarter, the stock posted a quick ratio of 3.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.24, a number that is poised to hit 0.20 in the next quarter and is forecasted to reach 1.78 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
Compared to the last year’s volume of 2.82 million, its volume of 1.63 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 71.29%. Additionally, its Average True Range was 2.07.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 42.78%, which indicates a significant increase from 20.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.96% in the past 14 days, which was higher than the 61.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.55, while its 200-day Moving Average is $30.55. Nevertheless, the first resistance level for the watch stands at $35.82 in the near term. At $36.16, the stock is likely to face the second major resistance level. The third major resistance level sits at $36.70. If the price goes on to break the first support level at $34.93, it is likely to go to the next support level at $34.39. Should the price break the second support level, the third support level stands at $34.04.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
There are currently 158,755K shares outstanding in the company with a market cap of 5.63 billion. Presently, the company’s annual sales total 329,000 K according to its annual income of 23,380 K. Last quarter, the company’s sales amounted to 120,860 K and its income totaled 5,060 K.
